Biological
Vocimagene amiretrorepvec clinical trials
Also written Toca 511.
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 1
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses vocimagene amiretrorepvec is read from its arms, and is right about nine times in ten.
Testing it · 8
- Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed GlioblastomaWithdrawnPhase 2/3NRG OncologyNCT04105374Written as Vocimagene Amiretrorepvec
- A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511TerminatedPhase 1Tocagen Inc.NCT04327011Written as Toca 511 vector
- A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)WithdrawnPhase 1Tocagen Inc.NCT04089163Written as Toca 511
- A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of CareWithdrawnPhase 1Tocagen Inc.NCT02598011Written as Toca 511
- A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)TerminatedPhase 1Tocagen Inc.NCT02576665Written as Toca 511
- The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade GliomaTerminatedPhase 2/3Tocagen Inc.NCT02414165Written as Toca 511
- A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant GliomaCompletedPhase 1Tocagen Inc.NCT01156584Written as Toca 511 vector
- Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain TumorCompletedPhase 1Tocagen Inc.NCT01985256Written as Toca 511
Codes
What other systems call vocimagene amiretrorepvec · ClinicalTrials.gg INT001064
- MeSH (NLM) C000630228vocimagene amiretrorepvecOne source NLM
- UNII (FDA) DC4WO3WA4QVOCIMAGENE AMIRETROREPVECConfirmed FDA, NLM
- NCI Thesaurus C91734Vocimagene AmiretrorepvecOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630228 | vocimagene amiretrorepvec | One source NLM |
| UNII (FDA) | DC4WO3WA4Q | VOCIMAGENE AMIRETROREPVEC | Confirmed FDA, NLM |
| NCI Thesaurus | C91734 | Vocimagene Amiretrorepvec | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.